Journal
CLINICAL ONCOLOGY
Volume 25, Issue 10, Pages 604-609Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.clon.2013.06.004
Keywords
alpha Particles; beta electrons; radioimmunotherapy; targeted radiotherapy; vectors
Categories
Funding
- Cancer Research UK [11564] Funding Source: researchfish
- Cancer Research UK [A8993] Funding Source: Medline
Ask authors/readers for more resources
This review highlights recent progress in the development of anticancer radiopharmaceuticals. Molecularly targeted radiotherapy refers to the selective delivery of radionuclides that emit charged particles, such as alpha particles, beta or Auger electrons, to cancer cells via a targeting vector. The discovery of new molecular targets through systems biology and other approaches has widened the scope for radiopharmaceutical development. Innovations in antibody engineering and humanisation, recombinant DNA technology, conjugation chemistry and, increasingly, nanotechnology have provided new approaches to the delivery of radionuclides to cancer cells. The increased availability of radioisotopes that have not traditionally been considered for therapy, such as alpha particle emitters, has also broadened the indications for targeted radiotherapy. (C) 2013 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available